Innate immune responses in IL28B minor patients may have adapted to a different equilibrium compared with that in IL28B major patients. Our data will advance both understanding of the pathogenesis of HCV resistance and the development of new antiviral therapy targeted toward the innate immune system. Additional Supporting Information may be found find more in the online version of this article. “
“Cellular and plasma lipid levels are tightly controlled by complex gene regulatory mechanisms. Elevated plasma lipid content, or hyperlipidemia, is a significant risk factor for cardiovascular morbidity and mortality. MicroRNAs (miRNAs) are posttranscriptional regulators of

gene expression and have emerged as important modulators of lipid homeostasis, but the extent of their Stem Cell Compound Library purchase role has not been systematically investigated. In this study we performed high-throughput small RNA sequencing and detected ≈150 miRNAs in mouse liver.

We then employed an unbiased, in silico strategy to identify miRNA regulatory hubs in lipid metabolism, and miR-27b was identified as the strongest such hub in human and mouse liver. In addition, hepatic miR-27b levels were determined to be sensitive to plasma hyperlipidemia, as evidenced by its ≈3-fold up-regulation in the liver of mice on a high-fat diet (42% calories from fat). Further, we showed in a human hepatocyte cell line (Huh7) that miR-27b regulates the expression (messenger RNA [mRNA] and protein) of several key lipid-metabolism genes, including Angptl3 and Gpam. Finally, we demonstrated that hepatic miR-27b and its target genes are inversely altered in a mouse model of dyslipidemia and atherosclerosis. Conclusion: miR-27b

is responsive to lipid levels and controls multiple genes critical to dyslipidemia. (HEPATOLOGY 2013) Cellular and plasma lipid levels are tightly controlled by complex feed-back and feed-forward mechanisms, which regulate the expression and activity of key metabolic genes1 at both the transcriptional and posttranscriptional levels.2, 3 Dysregulation of lipid metabolism can lead to Levetiracetam hyperlipidemia, a major risk factor for cardiovascular disease.4 Several key processes for regulating cellular and systemic lipid levels have been identified5; however, posttranscriptional mechanisms remain less well characterized. MicroRNAs (miRNAs) are short (≈22 nucleotides) noncoding RNAs that regulate gene expression at the posttranscriptional level.6, 7 They serve as stable plasma biomarkers for various disorders,8 are important factors in the pathogenesis of several diseases,9, 10 and are promising targets of novel therapeutic strategies.11, 12 In regard to lipid metabolic control, miRNAs have recently been found to modulate cholesterol homeostasis.13 In vivo inhibition of a liver-specific miRNA, miR-122, significantly lowers plasma cholesterol levels in both mice and nonhuman primates.